Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGNGet Free Report) in a research report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

Check Out Our Latest Report on Evogene

Evogene Price Performance

EVGN stock opened at $1.95 on Friday. Evogene has a 1 year low of $1.70 and a 1 year high of $10.40. The stock’s fifty day moving average price is $2.62 and its 200-day moving average price is $4.77. The company has a market cap of $10.47 million, a P/E ratio of -0.49 and a beta of 1.43.

Evogene (NASDAQ:EVGNGet Free Report) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The firm had revenue of $0.91 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGNFree Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

See Also

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.